Pingping Cao

机构：Nanjing Medical University · ORCID：0009-0009-8583-3928

发表论文 32 篇 · 总被引 205 次 · h-index 6

代表论文

• Toward the next generation EGFR inhibitors: an overview of osimertinib resistance mediated by EGFR mutations in non-small cell lung cancer (2023 · Cell Communication and Signaling · 被引 96)
• Postoperative Injection of a Triptolide‐Preloaded Hydrogel Prevents the Recurrence of Glioblastoma by Dual‐Pathway Activation of Ferroptosis (2024 · Small · 被引 17)
• Prolonged exposure to environmental levels of microcystin-LR triggers ferroptosis in brain via the activation of Erk/MAPK signaling pathway (2023 · Ecotoxicology and Environmental Safety · 被引 14)
• Genome‐scale CRISPR–Cas9 screen identifies PAICS as a therapeutic target for EGFR wild‐type non‐small cell lung cancer (2024 · MedComm · 被引 13)
• TNFRSF19 within the 13q12.12 Risk Locus Functions as a Lung Cancer Suppressor by Binding Wnt3a to Inhibit Wnt/β-Catenin Signaling (2023 · Molecular Cancer Research · 被引 7)
• Suit the Remedy to the Case: An Activatable DNA Damage Initiator for Postsurgical Therapy of Glioblastoma with TP53 Mutations (2024 · ACS Materials Letters · 被引 5)